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RNA silencing mediated by microRNAs (miRNAs) is a recently discovered gene regulatory 
mechanism involved in various aspects of biology, such as development, cell differentiation and 
proliferation, and innate immunity against viral infections. miRNAs, which are a class of small 
(21–25 nucleotides) RNAs, target messenger RNA (mRNA) through incomplete base-pairing 
with their target sequences resulting in mRNA degradation or translational repression. Although 
studies of miRNAs have led to numerous sensational discoveries in biology, many fundamental 
questions about their expression and function still remain. In this review, we discuss the dynamics 
of the mammalian miRNA machinery and the biological function of miRNAs, focusing on RNA 
viruses and the various therapeutic applications of miRNAs against viral infections.
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human) with a focus on RNA virus infection and the development 
of novel technologies that take advantage of the particular charac-
teristics of miRNA for therapeutic purposes.
Basic knowledge of mammalian miRna
stRuctuRe of miRna pRocessing machineRy
At present, siRNAs, which are exogenously induced double-
stranded or short hairpin RNAs, are utilized as an essential tool for 
gene- specific silencing. In contrast, miRNAs play an important role 
in both post-transcriptional and translational regulation (Bartel, 
2004). To obtain insights into the molecular mechanisms underly-
ing RNA silencing pathways, the three-dimensional structures of 
proteins participating in miRNA biosynthesis have been deduced 
(see review in Jinek and Doudna, 2009). The protein structure of the 
human miRNA processing machinery is illustrated in Figure 1.
Drosha, a nuclear RNaseIII enzyme, has two RNaseIII catalytic 
sites with a double strand RNA binding domain (dsRBD) at the 
C terminus (Lee, 2003) and a proline-rich domain and arginine/
serine-rich domains at the N terminus. DGCR8 has two dsRBDs 
and a WW domain containing two conserved tryptophan (W) 
residues. DGCR8 binds to the base of the long primary transcript 
(pri-)miRNA hairpin, positioning Drosha to cleave the pri-miRNA 
stem at a distance of 11 base pairs from the junction between the 
dsRNA stem and the flanking ssRNA regions (Han et al., 2006). 
The core region of human DGCR8 has been crystallized (Sohn 
et al., 2007).
Dicer, cytoplasmic RNaseIII, has ATPase and helicase domains 
at the N-terminus, followed by DUF283 (unknown function) 
and PAZ (PIWI/Argonaute/Zwille) domains, in addition to two 
RNaseIII domains and one dsRBD (Bernstein et al., 2001; Jinek 
and Doudna, 2009). The PAZ domain binds specifically to the 3′ 
end of single-stranded RNA. The crystal structure of Giardia Dicer 
suggests that it functions as a molecular ruler by anchoring the 3′ 
dinucleotide of the dsRNA bound to the PAZ domain, cleaving it at 
intRoduction
The human genome is about 3,300 Mb in size and comprises 1% 
exons and 24% introns (the remainder being transposons (45%) 
and repetitive sequences). It is assumed that less than 40,000 
 protein-coding genes are present (Lewin, 2004), so why do we 
have such a large genome containing so many non-coding regions? 
Historically, the idea that RNA regulates the gene expression profile 
of each cell was proposed by Britten and Davidson (1969). This 
hypothesis was realized in the 1990s, especially after the first key 
finding (in Caenorhabditis elegans) that double-stranded RNA is 
cleaved by the ribonuclease (RNase), Dicer, into small, ∼22 nucle-
otide (nt) RNAs, and induces gene silencing (RNA silencing) (Fire 
et al., 1998). Subsequent extensive studies and computer-based bio-
informatics approaches shed light on “the world of small RNAs”, 
which consist of small RNAs (∼20–30 nt) with a variable origin, 
including exogenous and endogenous short interfering RNAs 
(siRNA), Piwi (P-element-induced whimpy testes)-interacting 
(pi)RNAs and microRNAs (miRNAs) (see review in Zamore and 
Haley, 2005; Choudhuri, 2009).
The post-transcriptional gene silencing (PTGS) mechanism 
mediated by these small RNAs plays a fundamental role in devel-
opment, differentiation, proliferation, and transposon mobility 
(Bartel, 2004; Zamore and Haley, 2005; Berkhout and Jeang, 2007). 
Currently, nearly 1,000 mature human miRNAs are registered in 
the miRNA data base (http://www.mirbase.org/). Although our 
knowledge of small RNAs is expanding rapidly, the expression 
profiles and function of many of these miRNAs remains unclear. 
In this expanding field of science, it seems impossible to cover all 
the aspects of miRNA research and there are already numerous 
reviews of miRNA focusing, for example, on the immune system 
(Baltimore et al., 2008; Lodish et al., 2008; Xiao and Rajewsky, 2009; 
O’Connell et al., 2010), cancer (Croce, 2009), and virus-encoded 
miRNAs (Gottwein and Cullen, 2008; Boss et al., 2009; Cullen, 
2009). Here, we discuss recent topics regarding miRNAs (mostly 
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Human miRNAs are present within the introns of coding genes 
and the introns and exons of non-coding transcripts (Berkhout and 
Jeang, 2007). pri-miRNA, which is transcribed by RNA polymerase 
II, forms a distinctive hairpin structure with a 5′-capped poly(A) 
tail. This characteristic hairpin structure is recognized by Drosha 
(Bartel, 2004). Drosha forms a complex with DGCR8 and cleaves 
pri-miRNA at the unpaired flanking regions, leaving a monophos-
phate group at the 5′ ends and a two-nt overhang at the 3′ ends 
(Han et al., 2006). The products of these processed pri-miRNAs 
are ∼70-nt stem-loop RNA intermediates (pre-miRNA). The pre-
miRNA is exported from the nucleus to the cytoplasm by exportin 
5 in a Ran guanosine triphosphate-dependent manner (Lund et al., 
2004), where it is processed by Dicer.
Human Dicer works together with its dsRNA-binding partner 
proteins, TRBP and PACT, to cleave pre-miRNA into ∼22-nt long 
dsRNAs, though TRBP and PACT are not essential for cleavage 
(Haase et al., 2005; Lee et al., 2006). The complex formed by Dicer, 
dsRNA, TRBP, and PACT then recruits Argonaute to form the RNA-
induced silencing complex (RISC) loading complex (Chendrimada 
et al., 2005). Finally, Argonaute delivers mature miRNA to the 
processing bodies (PBs) or stress granules (SGs), where the target 
messenger RNA (mRNA) is located (Peters and Meister, 2007).
Mature miRNA, carried by Argonaute, can destroy target mRNA 
with complementary sequences or repress protein synthesis by 
partially binding to the 3′ untranslated region (UTR) of target 
a fixed distance from that end, and generating products of defined 
length (Macrae et al., 2006). A connector helix may be the main 
determinant of product size.
TAR RNA-binding protein (TRBP) and PACT have similar 
structures, with three dsRBDs that directly interact with each other 
and with Dicer (Kok et al., 2007). Interestingly, PACT is an activa-
tor of protein kinase R (PKR), whereas TRBP is an inhibitor. One 
dsRBD known as Medipal in TRBP is a protein–protein interaction 
domain that binds Merlin, Dicer, and PACT. The TRBP C-terminus 
of Madipal interacts with Dicer via its ATPase/Helicase domain 
(Daniels et al., 2009).
Like Dicer, the Argonaute protein also has a PAZ domain, which 
binds to the 3′ end of guide RNA (Wang et al., 2008). The MID 
domain provides a binding pocket for the 5′-phosphate of guide RNA 
and the PIWI domain adopts an RNaseH fold and has endonuclease 
activity (Boland et al., 2010). In humans, there are four genes encod-
ing Argonaute and only one of these, Ago2, has endonuclease activity. 
The mechanism by which the Ago protein mediates translational 
repression remains controversial and may be different in different 
cell types (for details, see review in Peters and Meister, 2007).
Biogenesis of miRna
Although there are considerable variations in miRNA biogenesis 
and regulatory pathways (Winter et al., 2009), a representative 
pathway is shown in Figure 2.
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FiguRe 1 | Structure of the human miRNA processing machinery. The 
predicted structures of Drosha and DGCR8 in the nucleus are shown in the 
upper panel. Dicer1, TRBP, and PACT interact in the cytoplasm and recruit 
Argonaute2. TRBP and PACT have a similar structure with the three dsRBDs 
(green). Two RNase III domains (red) are common in Drosha and Dicer1. PAZ 
domain (blue) is common in Dicer1 and Argonaute2. In Argonaute2, MID domain 
provides a RNA binding pocket and PIWI domain has endonuclease activity (light 
blue) (see the text in detail).
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To identify the functionally important targets of miRNA, Selbach 
et al. (2008) employed a novel isotope pulse-labeling method of pro-
teins (pulsed stable isotype labeling with amino acids in cell culture, 
pSILAC) in combination with mass-spectrometry-based proteomics. 
They evaluated changes in production of ∼5000 proteins associated 
with the overexpression of several miRNAs in HeLa cells, which 
included tissue-specific miRNAs not expressed in HeLa cells (miR-1 
and miR-155) and those expressed ubiquitously (miR-16, miR-30a, 
and let-7b). This pSILAC technology was quite useful in identifying 
functionally important targets of miRNAs at the protein level. They 
demonstrated that a single miRNA can directly downregulate the 
production of hundreds of proteins, and identified the seed sequence 
in the 3′ UTR as the primary motif for miRNA-mediated regulation 
of protein synthesis, probably acting via both mRNA degradation 
and translational repression. Notably, the repressive effect on indi-
vidual proteins was relatively small, which may reflect the paucity 
(less than 3) of seed sites for each miRNA in individual target 3′ 
UTRs. Importantly, the results obtained from miRNA overexpression 
systems are equivalent to those obtained from knock down systems, 
confirming that their conclusions were not experimentally biased.
Baek et al. (2008) demonstrated the proteomic impact of over-
expressed miRNAs (miR-1, miR-181, and miR-124) using the same 
SILAC technology. They also analyzed the relationship between 
mRNA. Because seed sequences of only 7–8 nt are required to 
loosely  base-pair with the target sequence, a single miRNA is esti-
mated, on average, to broadly target ∼200 species of RNA (Lewis 
et al., 2005; Bartel, 2009).
high thRoughput pRofiling analysis
Expression of miRNAs may change temporally, in a spatial and 
tissue- or cell-type-specific manner. Large scale cloning and expres-
sion analyses of mammalian miRNAs were carried out by Landgraf 
et al. (2007) and the expression profiles of distinct human and 
mouse mature miRNAs were characterized. Comparison of miRNA 
expression between the hematopoietic system and all other organ 
systems indicated that only five miRNAs are highly specific to cells 
of the hematopoietic lineage (miR-142, miR-144, miR-150, miR-
155, and miR-223). It is worth noting that species-specificity is 
also demonstrated by the data; miR-150 and miR-155 are highly 
hematopoietic-specific in mice, but not in humans. They also 
observed that the miRNA expression profiles of different sorted 
mature T cell types were similar and clustered together, and that no 
striking differences in the miRNA expression profiles of the differ-
ent myeloid sub-lineages existed, except in granulocyte/monocyte-
specific miR-223 expression. Thus, exclusive expression of miRNA 
by particular tissues or cell types is rare.
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FiguRe 2 | Biogenesis of miRNA. Drosha recognizes the specific hairpin structure 
of pri-miRNA and, in the presence of the cofactor DGCR8, cleaves the un-stemmed 
ssRNA region of pri-miRNA to generate pre-mRNA. Pre-miRNA is exported by 
exportin 5 to the cytoplasm, where Dicer recognizes the hairpin structure of dsRNA 
and cleaves, and short deRNA is generated. TRBP and PACT bind to Dicer, and 
Argonaute is recruited to form the RISC loading complex. Mature miRNA, 
complexed with Argonaute, is known as the transfer strand and is carried to the 
P-body or stress granules (SG), depending on the condition of the cell. The mRNA is 
rich in P-bodies, and either degradation or translational repression of target mRNA 
occurs. The red arrowheads in Pri- and Pre-miRNA indicate cleavage sites.
Frontiers in Microbiology | Virology  October 2010 | Volume 1 | Article 108 | 4
Tsunetsugu-Yokota and Yamamoto Mammalian microRNAs and RNA virus infection
between HIV-1 replication and the expression of miRNA and 
PCAF/Tat. Thus, the miRNA biogenesis machinery contributes to 
host defense against HIV-1. However, additional cellular miRNAs, 
or other inhibitory mechanisms, may also be involved in virus–host 
interactions.
Mammals have a single Dicer gene, Dicer1. Inactivation of 
Dicer1 in mice causes embryonic lethality or severe damage to tis-
sue morphogenesis, cell differentiation and development (Bernstein 
et al., 2003). Otsuka et al. (2007) managed to produce such Dicer1-
deficient mice expressing low levels of Dicer in some tissues and 
almost none in peritoneal macrophages. Using these mice, they 
demonstrated for the first time in vivo that miRNAs target the RNA 
genome of vesicular stomatitis virus (VSV). Interestingly, these 
Dicer1-deficient mice were susceptible to VSV, but not to other 
RNA viruses, including encephalomyocarditis virus (EMCV), lym-
phocytic choriomeningitis virus (LCMV), and Influenza A virus. 
Computer prediction models allowed them to select 24 candi-
date miRNAs to potentially target the positive-strand sequence 
of VSV. They demonstrated that miR-93 and miR-24 suppress 
VSV replication by targeting the P (polymerase cofactor)- and 
L (RNA-dependent RNA polymerase)-encoding regions of VSV, 
respectively.
cellulaR miRnas diRectly taRget viRal Rna
For the inhibition of virus replication, the seed sequences of miRNA 
must be complementary to the viral targets for silencing (Gottwein 
and Cullen, 2008). Although a number of computer-based pro-
grams that search for homology between human miRNAs and viral 
genomes can predict complimentarity to various regions of viral 
sequences, the effects of RNAi need to be demonstrated in infected 
cells. The following are examples of successful approaches used to 
identify cellular miRNAs that target viral RNA.
Lecellier et al. (2005) found no evidence of virus-derived siRNAs 
within primate foamy virus type 1 (PFV-1), which is a complex 
retrovirus closely related to HIV and encodes two accessory fac-
tors, Bet and Tas. Instead, by fusing viral fragments to the UTR of 
a GFP-tagged reporter gene, they found that the 3′ end fragment 
of the PVF-1 genome, which encodes Bet and Env/Bet proteins 
(and is also within the 3′ UTR), reduced GFP levels and was a 
target for miR-32. Thus, miR-32 exerts a direct, sequence-specific 
effect against PFV-1. Moreover, they demonstrated that the viral 
Tas protein interacts with cellular miRNAs and acts as a broadly 
effective silencing suppressor. Similar, virally coded, RNA silenc-
ing suppressor (RSS) activity was shown for HIV-1 Tat (Bennasser 
et al., 2005), vaccinia virus E3L, influenza A virus NS1 and Ebola 
virus VP35 proteins (Haasnoot et al., 2007).
Huang et al. (2007) inserted DNA fragments from the 3′ UTR 
of HIV-1 RNA into the 3′ UTR of the pEGFP vector and identified 
the region targeted by a potential miRNA-mediated mechanism in 
resting primary CD4+ T cells. They found that miRNAs, such as 
miR-28, miR-125b, miR-150, miR-223, and miR-382, are abundant 
in resting T cells, but not in activated T cells, and the replication of 
latent viruses in patients on HAART was prevented by inhibiting 
these miRNAs. However, there are more than 100 cellular mRNA 
targets for each miRNA (Lewis et al., 2005) and the consequences 
of modulating the expression of these miRNAs may differ between 
T-cell subpopulations at distinct differentiation stages (see below). 
seed sequence matches and protein repression in HeLa cells and 
found that mRNAs with single 7-mer or 8-mer site matches, but 
not 6-mers, were significantly downregulated by miRNA. The seed 
sites within the 3′ UTRs were generally more effective than those 
in coding regions. Again, they demonstrated that the targeting 
principles elucidated from overexpressed exogenous miRNAs 
also apply to endogenous miRNA targeting at the level of protein 
downregulation, as argued by Selbach et al. (2008). We assume 
that coordinated post-transcriptional gene regulation by miR-
NAs contributes to the fine tuning of protein expression by cells 
in a tissue-, lineage-, differentiation-, proliferation-, or cytokine 
signal-specific manner. Accumulating knowledge about miRNA 
expression profiles and their biological functions will be used to 
build sophisticated bioinformatics programs to clarify various 
aspects of miRNA biology. Such computer-based tools for pre-
dicting the target genes of miRNAs are available at http://www.
targetscan.org/, http://www.microrna.org/ and other sites (Bartel, 
2009), and will prove helpful for the identification of targets with 
physiological relevance.
viRus–host inteRactions and miRna
Recently, miRNAs were broadly implicated in viral infection of 
mammalian cells, having either positive, or negative effects on 
virus replication and host immune responses. Herpes-family 
viruses, which have a large DNA genome, are known to encode 
viral miRNA (v-miRNA), probably for the regulation of their own 
replication and latency and to control cellular defense mechanisms. 
However, the existence of v-miRNA in smaller DNA and RNA 
viruses remains controversial. It is argued that small viruses have 
size constraints that mean a greater proportion of their genome 
is required for coding purposes and is, therefore, less likely to 
retain non-coding RNAs (Berkhout and Jeang, 2007). In contrast, 
long-term, latently infected viruses such as herpes viruses derive a 
greater survival benefit from utilizing the cellular miRNA machin-
ery (Cullen, 2010).
Because DNA virus-encoded v-miRNAs have been reviewed in 
detail elsewhere (see review in Gottwein and Cullen, 2008; Boss 
et al., 2009; Cullen, 2009), we will focus on the interaction of cellular 
miRNAs with RNA viruses as a host defense mechanism against 
viral infection.
implications of miRna contRiButions to antiviRal activity
In plants, worms and flies, RNA silencing suppresses the mobiliza-
tion of endogenous retroviruses. Therefore, it is expected that the 
miRNA silencing machinery may be involved in defense against 
viral infections in vertebrates. Triboulet et al. (2007) demonstrated 
that, by silencing RNase III, Dicer, or Drosha, HIV-1 replication 
is inhibited in PBMCs from HIV-infected donors and in latently 
infected U1 cells in which HIV-1 is not efficiently transcribed 
through its promoter (the long terminal repeat, LTR) due to a 
Tat mutation. They analyzed the level of miRNA in Jurkat cells 
using microarray analysis and found that a polycistronic miRNA 
cluster, miR-17/92, was markedly decreased upon HIV-1 infection. 
Although miR-17/92 does not directly target the viral genome, the 
histone acetylase, PCAF, which is a cofactor for Tat transactiva-
tion, has four potential target sequences for miR-17-5p and 20a in 
its 3′ UTR. Triboulet et al. clearly demonstrated the  relationship 
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of Cyclin T1, required for transactivation by HIV-1 Tat, increases 
during macrophage differentiation and enhances HIV-1 replication 
within macrophages (Liou et al., 2002). A recent report indicates 
that miR-198-mediated repression of Cyclin T1 may contribute 
to HIV-1 replication during monocyte differentiation into mac-
rophages (Sung and Rice, 2009).
These results indicate that RNA viruses utilize cellular miRNAs 
to manipulate the expression of cellular genes to enhance their own 
survival and expansion. The known interactions between cellular 
miRNA and RNA viruses are summarized in Figure 3.
effects of miRnas on immune cell diffeRentiation  
and viRal infection
The conditional knockdown of Dicer in murine T or B lymphocytes 
causes abnormal lymphocyte differentiation (Cobb et al., 2005; 
Muljo et al., 2005). Antigen-induced immune cell differentiation 
is a key feature of host defense and elicits coordinated immune 
responses to protect the host from pathogens (Baltimore et al., 
2008). For example, profound changes in gene expression occur 
during antigen-induced CD8+ T cell differentiation in mice (Wu 
et al., 2007). Wu et al. identified seven miRNAs (miR-16, miR-21, 
miR-142-3, miR-142-5, miR-150, miR-15b, and let-7f) frequently 
expressed in all T cells and observed alterations in the miR-21 
expression signature as cells differentiated from naïve to effector 
cells. We have also shown the existence of similar, but not identi-
cal, differentiation-associated miRNA expression profiles in human 
CD8+ T lymphocytes. The function of these miRNAs requires fur-
ther investigation.
Recent microarray analysis studies show that monocyte dif-
ferentiation into dendritic cells is regulated and coordinated by 
miR-34a and miR-21 (Hashimi et al., 2009). JAG1 and WNT1 were 
identified as targets for these miRNAs using a bioinformatic target 
ranking system. Considering that monocyte-derived dendritic cells 
(MDDCs) are poor producers of HIV-1 compared with monocyte-
derived macrophages (Tsunetsugu-Yokota, 2008), it is highly likely 
that miRNA expression associated with cell differentiation from 
monocytes to either macrophages or MDDCs may also regulate 
HIV replication in monocytes (Wang et al., 2009). Although such 
differentiation-associated miRNAs have any impact on virus rep-
lication within infected cells remains to be addressed, the results of 
extensive miRNA profiling analyses of viral infections both in vitro 
and in vivo will be highly informative for the diagnosis and treat-
ment of viral infections in humans.
theRapeutic application of miRnas  
to viRal infections
Knowledge regarding the basic biology and function of mammalian 
miRNAs has increased greatly in recent times. The idea of utilizing 
RNA interference by miRNA for genetic manipulation is already 
being realized. Taking advantage of the tissue-specificity of miRNAs, 
Kelly et al. inserted the target sequences of muscle-specific miRNAs 
(miR-133a and miR-206) into the 3′ UTR of Coxsackievirus A21 
(CVA21), a pathogenic picornavirus that causes lethal myositis and 
oncolysis in tumor-baring mice (Kelly et al., 2008). The result was 
tissue-specific attenuation that allowed the virus to replicate well 
in muscle cells without being pathogenic. Likewise, by incorporat-
ing target sites for the neuron-specific miR-124a into the 3′ end of 
Furthermore, because transfection of RNA or DNA into resting 
T cells is a very inefficient procedure, applying miRNA expression 
in a therapeutic context may be very difficult.
Using microarray technology, Pedersen et al. (2007) analyzed 
RNA derived from interferon (IFN)-stimulated cells and found that 
eight miRNAs induced by IFN had seed sequences that were 100% 
complementary with hepatitis C virus (HCV). Of these putative 
miRNAs, five (miR-196, miR-296, miR-351, mir-431, and miR-448) 
were able to attenuate HCV replication in Huh7 cells. miR-196 
and miR-448 did not prevent the replication of HCV containing 
mutant target sequences, indicating that the antiviral effect is not 
induced by non-specific alterations in cellular gene expression. 
Furthermore, miR-122, which is essential for HCV replication 
(Jopling et al., 2005), was downregulated in response to IFN-β. 
Thus, these results suggest that the modulation of the expression 
levels of these miRNAs has an important role in the antiviral effects 
of IFN-β against HCV. However, a recent analysis of liver biopsy 
samples from chronic hepatitis C patients revealed no correlation 
between miR-122 expression and viral load (Sarasin-Filipowicz 
et al., 2009). Moreover, most of the miRNAs that mediate the effects 
of IFN-β on HCV replication were present only at very low levels, 
even after IFN treatment, arguing against a protective role for these 
miRNAs. Nevertheless, the finding that IFN-treatment significantly 
reduces miR-122 expression in non-responders, as opposed to com-
plete responders, indicates the usefulness of miRNA profiling as a 
prognostic marker for IFN therapy.
alteRed expRession of cellulaR miRna upon viRal infection: 
pathogenicity
The involvement of RNAi in influenza virus infection was identi-
fied by knocking down Dicer in Vero cells, which lack type I IFN 
genes (Matskevich and Moelling, 2007). Any acute virus infection 
may alter the expression pattern of both mRNA and miRNA in 
infected cells. Li et al. (2010) analyzed miRNA expression profiles 
in the lungs of mice infected with a highly pathogenic 1918 influ-
enza A virus and compared them with those of mice infected with 
a non-lethal seasonal influenza A virus. By analyzing the inverse 
correlation between altered miRNA expression and the expres-
sion of predicted mRNA targets, they demonstrated that the target 
mRNAs of one altered miRNA, miR-200a, were associated with 
the type I IFN signaling pathway, which plays an important role in 
the pathogenesis in 1918 influenza A virus infection in mice (Kash 
et al., 2006). They also found that miR-223 indirectly downregu-
lated CREB activity, which is required for the maintenance of cell 
survival and growth.
Another example can be found in HIV-1 infection. Cells of the 
monocyte/macrophage lineage are susceptible to HIV-1 infection; 
however, only macrophages can support massive virus production. 
This differentiation-dependent restriction mechanism has been 
attributed to the distinct expression of the APOBEC3 subfamily by 
monocytes (Peng et al., 2007). Recently, Wang et al. (2009) reported 
that high expression of miR-28, miR-150, miR-223, and miR-382 
was correlated with low susceptibility of monocytes to HIV-1 
infection. Although the target mRNAs of these miRNAs were not 
identified, the results suggest that monocyte differentiation and 
HIV-1 susceptibility are linked by a common set of miRNAs. In 
relation to monocyte/macrophage differentiation, the expression 
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be problematic. To overcome the problem of non-specific gene 
transfer, Brown et al. (2007) systemically treated a mouse model 
of hemophilia B with a lentivirus vector expressing clotting fac-
tor IX (F.IX) under the control of a hepatocyte-specific promoter. 
Although F.IX is only expressed in the liver, an anti-F.IX immune 
response was elicited, probably due to off-target expression by the 
hepatocyte-specific promoter in hematopoietic cells. By inserting 
four tandem-repeat target sequences of the hematopoietic-specific 
miR-142-3p into the 3′ UTR of the transgene expression cassette, 
they were able to achieve sustained F.IX production in hemophilia 
B mice. In these mice, miR-142-3p levels were 50-fold higher in 
the spleen than in the liver. Importantly, the introduction of len-
tivirus containing miR-142-3p target sequences did not affect the 
normal in vivo level of miRNA, including that of miR-142-3p. Thus, 
by combining a highly cell lineage-specific promoter with PTGS 
using cell state- or lineage-specific miRNAs, the engineered len-
tivirus delivery system should make it possible to achieve specific 
expression of transgenes within the desired cells or tissues (Brown 
et al., 2007).
As described in the previous section (4.2), the abundantly 
expressed, liver-specific miRNA, miR-122, binds to two closely 
spaced target sites within the 5′ UTR of the HCV genome and 
is required to maintain high HCV RNA abundance in liver cells 
(Jopling et al., 2005, 2008). Interestingly, the same miR-122 bind-
ing site placed in the 3′ UTR of a reporter mRNA downregulated 
the 5′ UTR and between the structural and non-structural genes 
within the coding region of the poliovirus, an attenuated poliovirus 
vaccine lacking any neurovirulence was developed (Barnes et al., 
2008). Similar engineering strategies were also applied to the VSV 
by inserting neurotropic miR-125 target sequences into the 3′ UTR 
of the viral polymerase gene (Kelly et al., 2010) and to adenoviruses 
by inserting a hepatocyte-selective miR-122 target site into the 3′ 
UTR of the E1A transcription cassette (Cawood et al., 2009). The 
structures of these attenuated viruses are illustrated in Figure 4. 
In this context, Perez et al. successfully attenuated the influenza 
A virus by incorporating species-specific, non-avian microRNA 
(miR-93) targets into nucleoproteins. The result was attenuated 
viral activity in mice, but not in eggs as expected (Perez et al., 2009). 
Thus, miRNA-mediated control of viral replication is a promising 
technology that can be used to develop safe attenuated viruses for 
cancer therapy and vaccines.
The RNAi-based gene delivery systems using lentivirus vec-
tors have been developed for the control of HIV-1 infection, and 
such lentivirus can be utilized as potential AIDS vaccine candi-
dates (Morris and Rossi, 2006; Rossi et al., 2007; Yamamoto and 
Tsunetsugu-Yokota, 2008). Likewise, considering the therapeutic 
applications of miRNA, efficient in vivo miRNA delivery systems by 
lentivirus vectors are a promising gene-transfer medium. However, 
because the VSV envelope glycoprotein used to encapsulate the 
transfer gene is pantropic, transgene expression in all cells could 
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